@thxtomyfriends

Happy Holidays from NSGO-CTU 🎄

The A team

Amazing ESGO esgo Council evening

𝐄𝐍𝐆𝐎𝐓, 𝐍𝐒𝐆𝐎-𝐂𝐓𝐔 & 𝐆𝐎𝐆 𝐩𝐫𝐨𝐮𝐝𝐥𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐄𝐍𝐆𝐎𝐓-𝐄𝐍6-𝐍𝐒𝐆𝐎/𝐆𝐎𝐆-3031/𝐑𝐔𝐁𝐘 𝐭𝐫𝐢𝐚𝐥. rb.gy/sqxq7u #Endometrial #Cancer #RUBY #NSGO #ENGOT #Dostarlimab #ESMO #SGO

Mansoor Mirza presenting practice changing Ruby trial results at #SGOmtg ✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer ✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49) ✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7) ✅dMMR ORR 77.6% w durable response & well-tolerated

📢👏🏻🏆Congratulations to Mansoor Mirza and the #RUBYtrial team and to patients who hopefully will can benefit from #immuntherapy💉🏥🧪 in advanced #endometrialcarcinoma

#SGOMtg: A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo. Read full results of RUBY trial: nej.md/40lFbBN

Endometrial cancer patient Sarah Greene thanks SGO for all the hard work. Standing ovation!! #SGOmtg #PatientsPurposeProgress #gyncsm

Exciting data! ENGOT is proud to be enrolling the XPORT-EC-042trial. #esgo2024

#SGOmtg visiting with friends

#SGOmtg Sarah Temkin @bpothuri

Niraparib (ZEJULA) fda.gov/FDAgov/Drugs/I…

"Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered" ascopost.com/issues/april-2… via @ascopost

Dr. Mirza Mansoor Mirza from Rigshospitalet on #ovariancancer x.com/ascopost/statu…

"Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life" ascopost.com/videos/2017-es… #oncology via @ascopost

Niraparib maintains quality of life in recurrent #ovariancancer bit.ly/2gWaAtV

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer shar.es/1V17g0 via @onclive

ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials - YouTube m.youtube.com/watch?v=cIEQ03…

EMA London